Candriam has appointed Tasuku Kitada as senior biotech analyst within its healthcare team.
Kitada will be part of Candriam’s Brussels-based biotech equity strategy team and will focus on technologies such as gene therapy and RNA interference. The Candriam Equities L Biotechnology fund currently has assets of around $730m.
Recently, Kitada has been a postdoctoral scholar in biological chemistry at the University of California and a postdoctoral associate in synthetic biology at the Massachusetts Institute of Technology (MIT).
Rudi Van den Eynde, Head of Thematic Global Equity, said : “Tasuku’s experience in the field of synthetic biology will be extremely valuable to us when assessing some of the newest and most promising emerging technologies like gene-splicing and antisense. Clinical innovation is evolving quickly and we need to make sure our knowledge in those fields remains top notch.”
Candriam is owned by New York Life Investment Management (NYLIM) and manages €91bn of assets.